Quarterly report pursuant to Section 13 or 15(d)

Earnings Per Share

v3.22.1
Earnings Per Share
3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Earnings Per Share

Note 16 - Earnings Per Share

 

Basic earnings per share (“EPS”) excludes dilution and is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or otherwise result in the issuance of common stock that shared in the earnings of the entity. Diluted EPS also utilizes the treasury stock method which prescribes a theoretical buy back of shares from the theoretical proceeds of all options outstanding during the period, and the if-converted method for convertible debt.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (in thousands):

    March 31, 2022     March 31, 2021  
    For the three months ended  
    March 31, 2022     March 31, 2021  
Net income - basic   $ 12,494     $ 1,057  
Interest on unsecured convertible promissory note     232       -  
Net income - diluted   $ 12,726     $ 1,057  
                 
Weighted average shares outstanding - basic     15,486       14,563  
Diluted shares- Stock Options     2,232       2,895  
Diluted shares- Stock Warrants     222       284  
Unsecured convertible promissory note     800       458  
Weighted average shares outstanding - diluted     18,740       18,200  

 

The following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive effect (in thousands):

 

    For the three months ended  
Anti-dilutive securities   March 31, 2022     March 31, 2021  
Common stock purchase warrants     455       455  
Stock Options     810       -  
Anti-dilutive securities     1,265       455